We are live on ! Find out more
FP

Flagship Pioneering Portfolio holdings

AUM $1.16B
1-Year Est. Return 67.93%
This Fund
S&P 500
This Quarter Est. Return
+48.19%
1 Year Est. Return
+67.93%
3 Year Est. Return
-39.17%
5 Year Est. Return
-45.89%
10 Year Est. Return
–
AUM
$5.49B
AUM Growth
+$1.87B
Cap. Flow
+$241M
Cap. Flow %
4.38%
Top 10 Hldgs %
99.42%
Holding
11
New
3
Increased
–
Reduced
2
Closed
–

Top Buys

Rank Stock Value
1
SGTX
Sigilon Therapeutics, Inc. Common Stock
SGTX
+$362M
2
FHTX icon
Foghorn Therapeutics
FHTX
+$243M
3
CDAK
Codiak BioSciences, Inc. Common Stock
CDAK
+$34.5M

Top Sells

Rank Stock Value
1
MCRB icon
Seres Therapeutics
MCRB
+$202M
2
DNLI icon
Denali Therapeutics
DNLI
+$196M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRNA icon
1
Moderna
MRNA
$21.5B
$3.23B 58.71%
30,871,524
– –
SGTX
2
DELISTED
Sigilon Therapeutics, Inc. Common Stock
SGTX
$498M 9.07%
+797,721
New +$362M
MCRB icon
3
Seres Therapeutics
MCRB
$48.1M
$360M 6.54%
733,699
-344,889
-32% -$202M
RUBY
4
DELISTED
Rubius Therapeutics, Inc
RUBY
$291M 5.29%
38,296,526
– –
EVLO
5
DELISTED
Evelo Biosciences, Inc. Common Stock
EVLO
$277M 5.04%
1,145,003
– –
FHTX icon
6
Foghorn Therapeutics
FHTX
$285M
$257M 4.68%
+12,674,120
New +$243M
DNLI icon
7
Denali Therapeutics
DNLI
$3.67B
$229M 4.16%
2,730,263
-3,250,000
-54% -$196M
KLDO
8
DELISTED
Kaleido Biosciences, Inc. Common Stock
KLDO
$176M 3.21%
19,360,710
– –
CDAK
9
DELISTED
Codiak BioSciences, Inc. Common Stock
CDAK
$84.2M 1.53%
+2,607,303
New +$34.5M
AXLA
10
DELISTED
Axcella Health Inc. Common Stock
AXLA
$65.1M 1.19%
501,937
– –
SYRS
11
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$31.9M 0.58%
293,849
– –

Similar funds

AC
AltraVue Capital Bellevue, Washington $1.16B AUM 46.45% 1-Year Est. Return
BI
Bramshill Investments Naples, Florida $1.16B AUM 0.86% 1-Year Est. Return
SCP
Sandhill Capital Partners Buffalo, New York $1.16B AUM 12.37% 1-Year Est. Return
SFG
SNS Financial Group Minneapolis, Minnesota $1.16B AUM 13.88% 1-Year Est. Return
GAB
German American Bancorp Jasper, Indiana $1.16B AUM 25.7% 1-Year Est. Return
AMI
Amica Mutual Insurance Providence, Rhode Island $1.16B AUM 21.34% 1-Year Est. Return
FFP
FourThought Financial Partners Venice, Florida $1.16B AUM 24.95% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return

Flagship Pioneering's Q4 2020 Portfolio in Review

As of Q4 2020, Flagship Pioneering held 11 positions worth $5.49B, up 52% from $3.62B the previous quarter. Its ten largest holdings account for 99% of the portfolio.

Flagship Pioneering deployed $241M of net new capital in Q4 2020, opening 3 new positions. Its largest new stake was Sigilon Therapeutics, Inc. Common Stock: 797,721 shares worth $498M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Seres Therapeutics, an estimated $202M trimmed.

  • Flagship Pioneering's largest Q4 2020 buy was Sigilon Therapeutics, Inc. Common Stock: 797,721 shares worth $498M.
  • Flagship Pioneering's biggest Q4 2020 reduction was Seres Therapeutics, cutting an estimated $202M.
  • Flagship Pioneering's ten largest holdings make up 99% of its $5.49B portfolio in Q4 2020.
  • Flagship Pioneering opened 3 new positions and closed 0 in Q4 2020.
  • Flagship Pioneering's portfolio value rose 52% quarter-over-quarter to $5.49B.

Based on Flagship Pioneering's 13F filing for Q4 2020, filed 16 Feb 2021.